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Background: Japanese encephalitis virus (JEV), a mosquito-borne zoonotic pathogen, is the sole etiologic agent of
Japanese Encephalitis (JE); a neurotropic killer disease which is one of the major causes of viral encephalitis
worldwide with prime public health concern. JE was first reported in the state of West Bengal, India in 1973. Since
then it is being reported every year from different districts of the state, though the vaccination has already been
done. Therefore, it indicates that there might be either partial coverage of the vaccine or the emergence of
mutated/new strain of JEV. Considering this fact, to understand the JEV genotype distribution, we conducted a
molecular epidemiological study on a total of 135 serum/cerebrospinal fluid (CSF) samples referred and/or collected
from the clinically suspected patients with Acute encephalitis syndrome (AES), admitted in different district hospitals
of West Bengal, India, 2010.
Findings: JEV etiology was confirmed in 36/135 (26.6%) and 13/61 (21.3%) 2–15 days’ febrile illness samples from
AES cases by analyzing Mac-ELISA followed by RT-PCR test respectively. Phylogenetic analysis based on complete
envelope gene sequences of 13 isolates showed the emergence of JEV genotype I (GI), co-circulating with
genotype III (GIII).
Conclusion: This study represents the first report of JEV GI with GIII, co-circulating in West Bengal. The efficacy of
the vaccine (derived from JEV GIII strain SA-14-14-2) to protect against emerging JEV GI needs careful evaluation.
In future, JE outbreak is quite likely in the state, if this vaccine fails to protect sufficiently against GI of JEV.
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The mosquito-borne Japanese encephalitis virus (JEV) is
an enveloped, positive-sense single-stranded RNA virus,
member of the genus Flavivirus under the family Flavi-
viridae [1]. JEV is the sole etiologic agent of Japanese En-
cephalitis (JE); a neurotropic killer disease being one of
the major causes of viral encephalitis in human. Since
the isolation of this virus in Japan in 1935 [2], it has
spread worldwide becoming a major public health* Correspondence: shyamalenduchatterjee@gmail.com
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reproduction in any medium, provided the orproblem. Worldwide case-fatality rate of JE was recorded
to be 30% approximately with 30-50% of survivors devel-
oping permanent neurologic deficit/sequelae [3].
Recent studies have shown that the envelope (E) gene
is an established phylogenetic marker for JEV, since this
region is free from selective pressure that supports ob-
scure long-term evolutionary relationship [4]. Altogether
5 distinct genotypes have been identified among the JEV
strains [5] of which genotype III (GIII) is mostly circu-
lated in the Southeast Asian countries, including Japan,
South Korea, China, Taiwan, Vietnam, Philippines, and
India [6]. However, it was recently documented that GIII
is replaced by genotype I (GI) in South Korea, Thailandtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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has been introduced in the country recently [7]. In 1973 JE
outbreak was first recorded in the districts of Burdwan and
Bankura in West Bengal where 700 cases and 300 deaths
were reported [8,9]. Thereafter, several JE outbreaks took
place in the state [10-12]. Every year sporadic JE cases are
being reported indicating its endemicity in this state des-
pite the vaccination programme undertaken by the State
Health Department, Government of West Bengal [13]. In
addition, the geographic features, environmental factors
and socio-economic status of this state also favor JEV
transmission [14]. Moreover, the reports of JE incidences
in the state are the indications of either partial coverage of
the vaccine or the emergence of mutated/new strain of
JEV. Genetic variation of JEV circulating in West Bengal
has not yet been investigated and hence to ascertain the
same a molecular epidemiological study was undertaken.
Materials and Methods
A total of 92 serum and 43 cerebrospinal fluid (CSF)
samples were referred and/or collected from 135 clinic-
ally suspected pediatric-adolescent (0–20 years old) and
adult (≥ 21 years old) individuals with Acute encephalitisFigure 1 Map of West Bengal showing the location of sample collectisyndrome (AES), showing high grade fever (≥39°c) for
2–15 days including any two of the following symptoms,
viz. headache, vomiting, stupor, delirium, abnormal
movements, presence of kernig’s sign, convulsions, neck
rigidity, altered sensorium, unconsciousness admitted in
8 different district hospitals, West Bengal during the
period from July to December in 2010 (Figure 1).
All the samples were tested for IgM antibody against
JEV by using IgM antibody-capture (Mac) ELISA kit
(National institute of virology, Pune, India), according to
the manufacturer’s protocol.
Only 61 JEV IgM negative samples with a history of ≤
3 days’ illness were screened and 200 μl of each of them
were used for virus isolation on C6/36 cell line accord-
ing to the standard protocol [13]. The tissue culture
fluids were collected from the samples producing prom-
inent cytopathic effect (CPE) and subjected for RNA ex-
traction by QIAamp RNA viral kit (Qiagen, GmbH,
Hilden, Germany), following the manufacturer’s protocol.
To identify the isolates as JEV, reverse transcription-
PCR (RT-PCR) was carried out with the extracted RNA
(50 pg to 1μg) by Qiagen one step RT-PCR kit (Qiagen,
GmbH, Hilden, Germany), in accordance with theon areas.
Table 1 Background information of selected strains/isolates of JEV referenced in this study




Nakayama Japan, 1935 Human brain III U70413
JaGAr01 Japan, 1959 Mosquito III AF069076
JaoArS982 Japan, 1982 Mosquito III M18370
Ishikawa Japan, 1998 Mosquito I AB051292
JaNAr0102 Japan, 2002 Mosquito I AY377577
Fu Australia,1995 Human II AF217620
WTP-70-22 Malaysia ,1970 Mosquito II U70421
PhAn1242 Philipines,1984 Pig serum III U70417
Muar Malaysia, 1952 Human V HM596272
691004 Srilanka, 1969 Human III Z34097
H49778 Srilanka, 1987 Human III U70395
DH20 Nepal, 1985 Human III U03690
VN118 Vietnam, 1979 Mosquito III U70420
K94P05 Korea, 1994 Mosquito I AF045551
KV1899 Korea, 1999 Pig I AY316157
K91P55 Korea, 1991 Mosquito I U34928
GP78 India, 1978 Human III AF075723
733913 India, 1973 Human brain III Z34095
P20778 India, 1958 Human III Z34096
R53567 India, unavailable unavailable III U70418
782219 India, 1982 Human III U70402
826309 India, 1982 Human brain III U70403
R53567 India, unavailable unavailable III U70418
014178 India, 2001 Human blood III EF623987
04940-4 India, 2002 Mosquito III EF623989
057434 India, 2005 Human blood III EF623988
78124 India, 1978 Human III U70387
JEV-GKP-0945054 India, 2009 Human CSF I HM156572
P3 China, 1949 Mosquito III U47032
SA14 China, 1958 Mosquito III U14163
SA14-14-2 China, unavailable Vaccine III D90195
GZ04-36 China, 2004 Mosquito III DQ404112
XZ0934 China, 2009 Mosquito V JF915894
SH-53 China, 2001 Mosquito I AY555757
JKT1749 Indonesia, 1979 Mosquito II U70405
JKT9092 Indonesia, 1981 Mosquito IV U70409
JKT7003 Indonesia, 1981 Mosquito IV U70408
JKT5441 Indonesia, 1981 Mosquito II U70406
2372 Thailand, 1979 Human I U70401
Chiang Mai Thailand, 1964 Human III U70393
HK8256 Taiwan, 1972 Mosquito III U03691
IND/10/WB India, 2010 Human CSF III JN189785
IND/10/WB/JEV28 Midnapore, India, 2010 Human CSF I JN703381
IND/10/WB/JEV21 Midnapore, India, 2010 Human CSF I JN703382
IND/10/WB/JEV38 South 24 Pgs, West Bengal, India, 2010 Human CSF III JN968470
IND/10/WB/JEV37 Hooghly, West Bengal, India, 2010 Human serum III JN968471
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Table 1 Background information of selected strains/isolates of JEV referenced in this study (Continued)
IND/10/WB/JEV44 Malda, West Bengal, India, 2010 Human CSF III JN968468
IND/10/WB/JEV41 Malda, West Bengal, India, 2010 Human CSF III JN968469
IND/10/WB/JEV40 Howrah, West Bengal, India, 2010 Human CSF III JN968472
IND/10/WB/JEV39 Birbhum, West Bengal, India, 2010 Human CSF III JN968473
IND/10/WB/JEV42 Murshidabad, West Bengal, India, 2010 Human serum III JN968474
IND/10/WB/JEV43 Murshidabad, West Bengal, India, 2010 Human serum III JN968475
IND/10/WB/JEV35 Nadia, West Bengal, India, 2010 Human serum III JN968476
IND/10/WB/JEV36 Nadia, West Bengal, India, 2010 Human serum III JN968477
MVEV-1-51 Australia, 1951 Human AF161266
All strains/isolates are JEV, except Murray valley encephalitis virus strain (MVE-1-51) used as out group for phylogenetic analysis in this study.
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pairs [13] that specific for structural E gene sequence of
JEV. The PCR products were separated by electrophor-
esis on 1% agarose gel, stained with ethidium bromide.
RT-PCR amplicons were purified using the Qiagen gel
extraction kit (Qiagen, GmbH, Hilden, Germany), accord-
ing to the manufacturer’s protocol, followed by direct se-
quencing using the BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, CA,
USA), as per the manufacturer’s instructions and the pro-
ducts were analyzed using an automated DNA sequencer,
3130XL Genetic Analyzer (PE Applied Biosystems, Foster
city, CA, USA). The 1,500 nucleotides generated complete
sequences of the JEV E gene that were edited and cor-
rected using the Finch TV software (http://www.geospiza.
com). Multiple sequence alignment and phylogenetic ana-
lysis were performed by using CLUSTALW (www.ebi.ac.
uk/Tools/clustalw2/index.html) and MEGA version 5.0
software (www.megasofteware. net). The phylogenetic tree
was constructed by the neighbor-joining method, tested
with Kimura 2-parameter model.
Results
Out of 135 samples, only 36 (26.6%) samples were reactive
to JEV specific IgM antibody, of which 23 (63.8%) and 13
(36.1%) samples were CSF and serum respectively. Only 61
of the remaining 99 JEV IgM negative samples having the
history of ≤ 3 days of febrile illness were selected and subse-
quently subjected to tissue culture resulting in 19 samples
producing prominent CPE of which only 13 (21.3%) sam-
ples were identified as JE positive by RT-PCR method, con-
sisting of 8 (61.5%) from CSF and 5 (38.4%) from serum.
We have a total of 49 (36 IgM + 13 RT-PCR positive) JE
cases (36.2%) of which 30 (19 IgM + 11 RT-PCR positive)
were pediatric-adolescent (61.2%) and remaining 19 (17 IgM
+ 2 RT-PCR positive) were found to be adult cases (38.7%).
Moreover, the occurrence of JEV infection was recorded dur-
ing the month of July to December with the maximum num-
ber of cases (46.9%) observed in the month of September.
The Figure 2 shows the phylogenetic tree derived from
13 E gene sequences of JEV isolates along with 41previously published JEV strains, including 12 from India
and 29 from worldwide (Table 1). Dendrogram showed 2 E
gene sequences of the isolates (GenBank: JN703381,
JN703382) belonging to GI and comprising 89%-91%
nucleotide (nt) identity with 11 E gene sequences of other
isolates (GenBank: JN968468- JN968477, JN189785)
belonging to GIII (Figure 2). Moreover, these 2 GI E gene
sequences showed 99% nt similarity with each other
and were most similar (96%) with Japanese GI strain Ishi-
kawa (GenBank: AB051292), followed by 94%-95% nt simi-
larity with Indian isolate JEV-GKP-0945054 (GenBank:
HM156572). Eleven GIII E gene sequences showed 97%-
99% nt similarity with each other and 93%-98% nt similarity
with other Indian GIII strains, having the highest similarity
(97%-98%) with Indian P20778 strain (GenBank: Z34096).
Discussion
JEV infection is considered as a prime issue on public
health concern in West Bengal. The present study
reveals that 36/135 (26.6%) and 13/61 (21.3%) samples
were positive to JE by Mac-ELISA and RT-PCR method
respectively. This observation is the proof of JEV infec-
tion in recent time and to detect the total number of JE
cases, ELISA negative acute samples (from ≤ 3 days’
febrile illness) should be confirmed by RT-PCR test.
JE incidences (61.2% vs. 38.7%) were higher in pediatric-
adolescent age group than adult because pediatrics were
infected possibly due to lack of immunity and adolescents
were directly exposed to the mosquito vector (Culex sp.) bite,
as they usually took active part in cultivation in crop-fields
where vectors usually breed. In the present study, JE was
found to occur in the monsoon period with the maximum
number of cases in September when the Culex mosquitoes
breed in the paddy fields covered with stagnant rain water.
However, we found that 86 [(99–61)+(61–13)] samples
with a history of 2–15 days’ illness were true JE negative
possibly due to either mishandling of samples which
damaged the IgM antibody/the viral titre or the presence
of another etiology responsible for AES.
In our previous reports we have achieved 36 JEV isolates

































































































Figure 2 Phylogenetic analysis of 13 JEV isolates in serum/CSF samples from AES patients, West Bengal. The Neighbor-Joining (NJ)
Phylogenetic tree based on complete envelope (E) gene nucleotide sequences of Japanese encephalitis virus (JEV) isolates/strains. The Murray
valley encephalitis virus strain (MVEV-1-51) was used as an out group for generating the rooted tree. The robustness of dendrogram was
evaluated by 1000 bootstrap pseudo replicates. Bootstrap values (≥50% of replicates) were shown in corresponding nodes. Horizontal branch
lengths are proportional to genetic distance and vertical branch lengths have no significance. Each taxon is named systematically by mentioning
the accession number, strain name, country of origin and year of isolation. The isolates’ sequences used in this study were marked with filled
circle and triangle symbols. Genotypes are indicated on the right. Scale bar indicates nucleotide substitutions per site.
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JN189782, JN189783, JN189784 and HQ891146 etc. (un-
published data). The present study, therefore, constitutes
the first report on E gene based phylogenetic analysis of the
JEV isolates from AES cases of West Bengal where JEV GI
has emerged very recently, co-circulating with JEV GIII.
Our study reveals that 2 isolates (GenBank: JN703381,
JN703382) belonging to GI of JEV from the coastal district
Midnapore (22.25°N 87.65°E and 23 meters above sea-
level) where this GI might be transmitted from other part
of India [7] or by the travellers returning from JE endemic
countries, possibly with JEV infection [15]. On the other
hand, this district has got many Lakes, swamps, forest and
rice fields which provide a wintering and staging grounds
for several migratory birds. Such areas are also very suit-
able for breeding and survival of mosquitoes. In view of
these conditions, GI of JEV might have been introduced
into West Bengal through migratory birds or cyclonic
wind-blown mosquitoes from newer geographic region
[16,17]. However, it is still unknown as to how JEV GI has
emerged in West Bengal exactly. Therefore, further studies
to determine the role of travelers, migratory birds and
wind-blown mosquitoes in JEV transmission are required.
The State Health Department of Government of West
Bengal undertook the vaccination programme against JE
in Midnapore in 2008 [13] using live attenuated JE
vaccine derived from GIII strain SA-14-14-2. In this
connection, the efficacy of the vaccine to protect
against GI of JEV needs careful evaluation. In near future,
there is a chance for an impending threat of JEV out-
break in this region/state, if this vaccine fails to protect
sufficiently against GI of JEV.
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